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Abstract: 
Purpose: The global financial crisis of 2008, considered by many economists to have been the most 
consequential since the great depression of the 1930s, altered the very fabric of global macro-economy and left 
many short and long-term impressions at various levels. Though the catastrophic effect of that meltdown 
penetrated the global market with lightning speed, the aftermath was rather uneven in its manifestation. 
Countries of American and European continent suffered severely but Asian countries were rather mildly affected 
and the reason behind this uneven perfusion could be the disparity in the economic environment at the 
microeconomic and macroeconomic levels in different continents. 
The Purpose of carrying out this research is to unveil the influence of internal microeconomic factors at firm 
level as well as external macroeconomic factors at country level on the overall stock price of Pharmaceutical 
companies of Asia's emerging market (India) and emerged markets of United States of America and Western 
European countries (Germany, France, UK, and Switzerland) after the global financial crisis of year 2008. 
Research Design/Methodology: During the present course of the investigation, secondary data of forty 
pharmaceutical companies from the year 2008 to the year 2017 has been employed to perform an empirical 
analysis. Moreover, an explanatory and comparative research design has been applied to corroborate the 
statistical outcome. 
For statistical analysis, EViews 10 student version, statistical software has been used on the dependent variable 
"Organization Stock Price" and several internal independent variables such as Return on Equity (ROE), Earnings 
Per Share (EPS), Dividend Per Share (DPS), Dividend Payout Ratio (DPR), PE ratio, firm's asset as well as few 
macroeconomic level independent variables such as corporate tax, inflation rate, GDP and exchange rate. 
Findings: Price movement of stocks is not independent in nature and doesn't follow a random walk. There are 
several factors responsible for the stock price movement such as investor sentiment, social, economic, 
environment and organization's operational and financial situation etc. This study shows how the aforementioned 
factors affect the stock prices of sample companies of emerging and emerged markets. 
Practical Implications: The outcome of this research could be helpful to managers to regulate organization's 
financial ratios and address the macroeconomic fluctuations to sustain the momentum of the stock price that will 
inadvertently increase the value of the company. From the investor's point of view, this study could provide them 
with better anticipation of future trends in the stock prices. 
Originality/Value: This study offers a contemporary review of the role of organizational and macroeconomic 
factors on the share price of companies and the stock market, thus contributes to the available literature in this 
domain. 
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The year 2008 brought about successive quarters of negative growth in the gross domestic product 
(GDP) of countries across the continents and had a damaging effect on the industries because economic 
downturns directly triggered a strong decline in the performance of various macroeconomic Key Performance 
Indicators (KPIs). Against that grim backdrop, global pharmaceutical industry fared better as they were not 
dangerously reliant on borrowing and therefore less exposed to the macro environment (Law, 2008). Although 
the pharmaceutical industry has always had its own share of problems, crash of 2008 had got two things going 
for them: they became more attractive for investors and unsettled times raised the demand for medicines. On the 
other hand, lack of global spending from governments and disparity in public medicines coverage inadvertently 
pushed the Pharmaceutical industry to uncharted territories. 
To thrive and excel in the testing times, pharmaceutical companies have come under great pressure to 
increase the efficiency and effectiveness of their operations. A looming patent cliff, with approximately 40% of 
the top-selling products worldwide going out of patent, has been resulting in companies losing their patents with 
the substantial impact of the revenue. There is also a consolidation of providers (doctors, group practices, 
hospitals, health systems) into larger accounts that have greater influence and economies of scale. Healthcare 
reform, driven by government policy, is reshaping the delivery of healthcare, from care coordination to 
reimbursement strategies, impacting behaviours and tactics within the marketplace (O’riordan et. al., 2016). 
Tightening regulations and ballooning healthcare cost have also impacted the healthcare operating models, 
reflecting the major shift in marketing tactics and customer engagement to reporting requirements by the 
government, payers, and providers. 
Amidst the mounting pressure coming from the aforementioned fronts, the fundamentals of the 
pharmaceutical industry have remained strong. The output of new drugs has been increasing and looks set to 
remain elevated over the next five years, largely based on the exciting new science of speciality medicines, to 
offset current and future patent expiries. After four years of falling or stagnating revenue from the year 2011to 
year 2014, the industry returned to growth in year 2015 with acceleration and improved operating margins in the 
year 2016. But, the new science of speciality medicines faces a persistent affordability gap between payers and 
governments budgets and the sales forecasts for new products. Some notable, recent new launches have been 
struggling to perform on account of concerns over the prevailing price sensitive climate. The key impact of 
accelerating revenue growth and improving operating margins, despite falling profit margins, on investors has 
been profound. The shift to speciality drugs, backed by strong pipeline, has opened up avenues to investors 
worldwide to favour stocks backed by value driven companies with focus on personalized patient outcomes by 
leveraging technology collaboration and driving operational efficiency. Aftermath of the year 2008 meltdown 
was momentum-driven move to the downside soaked in pessimism and massive liquidity crunch. 
The stock price is the primary indicator for investors to gauge the financial health of institutions. Listed 
institutions deploy their shares in the market to collect more funds to expand the business, unlike unlisted 
companies, who follow the Initial Public Offering (IPO) process. Moreover, stock price directly correlates with 
the amount of assets that the institution owns after the shareholder invests in the business, so this value is 
incurred on the balance sheet by the asset (Uddin, 2009). At firm-specific level, a bullish trend in the stock price 
of the firm reflects the confidence of investors in the fundamentals and performance of the firm and a bearish 
trend in the stock price of the firm reflects low confidence of investors in the fundamentals and performance of 
the firm. At the macroeconomic level, consumer prices, industrial production, exchange rate and the market rate 
of interest reflect bidirectional causation with stock prices affecting companies in both the short and long term. 
From the standpoint of financial experts and economist, there are many firm level and macroeconomic 
factors, play a pivotal role in the firm's financial and business operations differently and eventually drive the 
stock price. It is important to take into consideration that macroeconomic factors are more decisive in their 
impact on the oscillation of many firm-level factors controlling the stock rally. Therefore, the overall impact of 
the aforementioned factors varies, depending on the nature of business and industry in which firms operate. 
Basically, there are two types of industries, based on their sensitivity towards fluctuation in the economic cycle: 
 Cyclical Industries: Cyclical Industries and their stocks adhere tightly to the economic cycle. During the 
ascending economic phase, their stocks perform above average. However, during the descending 
economic phase, they get dipped into a downward direction. Example of cyclical industries such as 
automobile, Information technology, steel, tourism, fashion and so on. 
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 Non-Cyclical Industries: Since non-cyclical industries manufacture and distribute goods and services, 
which are always required for society such as food, power, medicine, and other utilities, their stocks do 
not tightly attached with the economic cycle. As a result, they tend to perform rather neutrally during 
both the ascending and descending phases of the economic cycle. 
Since medicines are one of the most basic needs for human being and animals to treat diseases and maintain 
a healthy life and pharmaceutical sector manufactures medicines to cater to this need of the global population, 
this industry is considered as a non-cyclical industry by economists and financial experts. 
The main objectives of this study to investigate the collective and individual effects of internal 
microeconomic factors and external macroeconomic factors on the market stock price of Pharmaceutical 
companies in emerging and emerged markets. In case of India: most of the Indian companies had positive net 
income throughout the sample period that in turn made all financial ratios such as EPS, DPS, DPR, and PE ratio 
stay in positive territory. Since most of the companies were having consistent profit, the distributed dividends to 
stockholders followed a regular pattern whereas in the emerged market, apart from few big companies, most of 
the companies registered negative net income that affected their EPS which turned out into no dividend to 
shareholders. Though the pharmaceutical sector was generally considered as a non-cyclical industry, the 
fluctuation in GDP, inflation, interest rate, corporate tax, and exchange rate didn't affect the stock price of Indian 
pharmaceutical sector any significantly. But, in the case of the emerged market, fluctuation in corporate tax and 
exchange rate were the main drivers affecting the pharmaceutical industry. 
2. Literature Review 
Literature review section begins by shedding light on key trends and advancements the pharmaceutical 
industry has seen in the last 40 years, with emphasis on its outlook post-2008 global financial crisis. 
Subsequently, it focuses on explicatory research works related to the significance of firm-level factors and 
macroeconomic factors on the price of stocks by analyzing the current and previous studies done by the various 
researches and academicians. This section also gives a chance to understand whether managers and financial 
experts can predict the momentum of stocks more precisely by employing the outcome of these studies. 
Furthermore, by going through the multiple research works and studies, this section also tries to get insight into 
possible relationship between macroeconomic factors and firm-specific factors and impact of their mutual 
influence. 
Pharmaceutical Industry Overview: 
In the last 40 years, the pharmaceutical industry has seen myriads of scientific, technological and legal 
advancements; however, the industry has also been marred by various controversies in areas of clinical trials 
management, approval mechanism, increased pricing and pharmacovigilance.  
 
 
Figure 1: Key Milestones in the pharmaceutical industry (Accenture Research, 2016) 
The key factors driving the Pharmaceutical industry are high R&D cost, the discrepancy between list 
and real price, rising ageing population and high affordability of drugs. As a result, the pharmaceutical industry 
is increasingly moving towards sustainability through more segmentation, robust regulatory framework and 
continuous breakthroughs in New Drug Discovery process. 
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In the wake of the Global economic crisis of 2008, where most of the Industry sectors had been hard hit, 
the pharmaceutical industry remained relatively unscathed. Key underlying factors behind that resilience were 
less sensitivity of economic trends and no price elasticity in time of crisis. 
Despite the relatively modest outlook, biotech and smaller pharmaceutical niche players are feeling the 
pressure because of depleting funding sources on account of the credit crunch. On the other end of the spectrum, 
larger players are also feeling the heat because of intensified scrutiny on healthcare budget by both public and 
private players and that has let to further cost containment measures to reduce drug prices, increase generic 
substitutions and demand for new drug formulation. In contrast with many other industries, pharmaceutical 
companies especially the larger once generally have a strong balance sheet with little debt and therefore have 
maintained stronger leverage in this time of crisis and uncertainty. 
2.1. Theoretical Basis and Development of Hypothesis 
Since financial ratios are the computational result of several inter-connected firm-level factors, it is one 
of the most prevalent ways to make an estimation of the financial and operational efficiency of a firm. The 
financial ratio can be used to determine irregularities in the implementation of the company's operational 
activities by comparing the financial ratio with that of previous years (Wild et al., 2008). Hence, financial ratios 
are being used as a major pointer in order to examine the current position of firm's profitability, liquidity, 
income, utilization of assets, liability, etc., by performing intra-comparative analysis between current report and 
previous report of the same firm or inter-comparative analysis among many firms. 
 
Return on Equity (ROE): Return on equity ratio (ROE) is considered a key measure of a company's 
earnings performance. The ROE provides information to common shareholders on how efficiently their money is 
being used. By analyzing ROE, shareholders can understand whether a firm is profit-enhancing or profit-
depleting and whether management has the profit-earnings ability or not (Kijewska 2016).  A rising ROE can 
signal that a company is able to grow profits without adding new equity into the Business, which dilutes the 
ownership share of existing shareholders (Thorp 2012). 
 
The higher Return on Equity (ROE) implies the higher profitability of firm that shows firm's 
management is utilizing investors' money in an efficient manner and investors can expect a higher rate of return 
on their investments which enhances the overall value of the firm and eventually increases the stock price. This 
ratio is also used to measure the ability of a company to use its own capital to generate profits for all 
shareholders, through both common and preferred stock. An increase in the company's stock price will provide a 
high return for investors. This will further increase the attractiveness of the company for investors. Karnawi 
Kamar (2017), conducted research to see the effect of Return on Equity and Debt to Equity ratio on the share 
price of listed cement companies at the Indonesian stock exchange. Statistical analysis revealed that together 
both factors produce a significant impact on the share price of companies. Moreover, ROE alone demonstrated a 
significant positive relationship with the share price of companies which proves that efficient utilization of 
inventors' money increases the price of shares. On the other hand, Haque and Faruquee (2013), studied the 
impact of fundamental factors on the share price of listed pharmaceutical companies of Dhaka stock exchange 
and found that ROE doesn’t have any effect on the share price of companies. Fouzan Al Qaisi et. Al. (2016), 
showed in their study that ROE didn’t have any effect on the stock price. However, Ursula Tamuntuan (2015), 
found a collective significance of  ROE, ROA, and EPS on the stock price of food and beverages companies at 
Indonesian stock market but, ROE alone didn't produce any significant effect on stock prices. 
Another study conducted by Fitri Sukmawati and Innes Garsela (2016), observed an inverse 
relationship between ROE and Share Price which means an increment in return on equity causes a decrement in 
the share price. Joanna L Saragih (2017), also found that ROE together with ROA and Debt-to-Equity ratio has 
no significant effect on the share price. However, ROE shows the insignificant positive partial effect on the share 
price. 
 
Earnings per Share (EPS): Earning per share (EPS) is generally one of the most important financial 
ratios, uses to evaluate the stock price and the value of the firm. Earnings per share measures the amount of net 
income earned against each share. In other words, this is the amount of money each share of stock would receive 
if all of the profits were distributed to the outstanding shares at the end of the year.  
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EPS are also a calculation that shows how profitable a company is from a shareholder’s perspective. 
Therefore, a larger company's profits per share can be compared to the smaller company's profits per share. 
EPS or basic earnings per share are calculated by subtracting preferred dividends from net income and 
dividing by the weighted average common shares outstanding. 
 
EPS are generally considered to be the single most important variable in determining a share's price. It 
is also a major component used to calculate the price-to-earnings valuation ratio (Besley 2006).  
EPS is a carefully scrutinized metric that is often used as a barometer to gauge a company's profitability 
per unit of shareholder ownership.  As such, earnings per share are a key driver of share prices.  It is also used as 
the denominator in the frequently cited P/E ratio (Md. Rashidul et. al., 2014). 
Pankaj Kumar (2017), studied the influence of EPS on the listed Indian automobile companies. The 
regression result showed a significant effect of EPS on the share price of automobile companies. Budhi 
Suparnihgsih (2017) and Ursula Tamuntuan (2015) found that EPS and other chosen variables simultaneously 
showed a significant effect on the share price of textile and garment companies of Indonesia stock exchange. 
Moreover, a partial significant positive effect of EPS was observed on the stock prices. Subramaniam V. A. and 
Tharshiga Murugesu (2013), studied the effect of the EPS on the share price of listed manufacturing companies 
in Sri Lanka. By employing regression techniques on the sample data, they found a strong significant positive 
relationship between EPS and Share Prices. 
Md. Bellal Hossain and A. H. M. Asaduzzaman (2017) and Sayed Akif and Umara Nareen (2016), also 
supported the significant positive effect on the stock prices of sample companies. Sanjeet Sharma (2011), found 
in his study that EPS showed a significantly positive impact on the share price of sample companies.  
 
Dividend per Share (DPS): Dividends are commonly defined as the distribution of earnings (past or 
present) in real assets among the shareholders of the firm in proportion to their ownership (Kapoor 2009). In 
other words, Dividend per share is the amount of perquisite issued by a firm for every common share 
outstanding. Dividends per share can be calculated by dividing the total number of dividends paid out by a firm, 
including interim dividends, over a period of time, by the number of shares outstanding (investopedia.com). 
 
In a favourable economic environment, raising the dividend amount and frequency gives a very 
prominent signal about the strong performance and higher profitability of the firm to its shareholders. However, 
at times in order to maintain the confidence of shareholders in the firm, many big firms pay dividends on a 
regular basis to their shareholders even after getting an average or weak financial result. 
Onyango Benedict Enrile (2018), conducted a research to understand the relationship between dividend 
per share (DPS) and the stock prices of listed companies at the Nairobi Stock Exchange, where author observed 
that DPS had a positive and significant effect on the share price of companies. Similarly, Sanjeet Sharma (2011), 
also observed a significant positive impact of DPS on share Prices. 
On the other hand, Sayed Akif and Umara Nareen (2016), studied fifty non-financial companies of 
Karachi stock exchange to check the role of dividend policy on stock prices volatility and they found a 
significant negative effect of DPS on stock prices of companies. Similarly, Sebastianus Laurens, (2018) and 
Hashemijoo, M., Ardekani, A. M., &Younesi, N. (2012) also found an inverse relationship between DPS and 
share price of companies. This inverse relationship between DPS and share price supports the dividend 
irrelevance theory. 
 
Dividend Payout Ratio (DPR): According to Akinsulire (2014), the dividend payout ratio is the ratio 
of ordinary dividends to retained earnings. It signifies that what portion of the net profits distributed to 
shareholders as dividends and what portion kept for internal reinvestment. A high payout ratio simply shows a 
liberal distribution of profits whereas a low payout ratio reflects a conservative distribution policy. However, 
from the share valuation model, Simon (2009) asserts that the value of a share depends very much on the amount 
of dividend distributed to shareholders such that the higher the dividend payout ratio, the more attractive the 
share is to the shareholders. 
Conversely, Hasan M, et, al (2015) found in their study that there is a negative impact of dividend 
payout ratio on the profitability of a firm in Pakistan's energy and textile sector. Similarly, Md. Bellal Hossain 
and A. H. M. Asaduzzaman (2017) did a study on the relationship between dividend policy and the stock price of 
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the listed fuel, power, and cement industry of Bangladesh. They applied the random effect panel data regression 
model and observed a negative influence of DPR on stock prices. 
Onyango Benedict Enrile (2018), conducted a research to understand the relationship between dividend 
per share (DPR) and the stock prices listed companies at the Nairobi Stock Exchange, where author observed 
that DPR didn't have any significant effect on the share price of companies whereas another research conducted 
by Hunjra et. al.(2014), to understand role of dividend policy, EPS, ROE, and profit after tax on the stock price. 
The regression result reflected a significant positive correlation between DPR and share price that shows 
distributing more dividends and keeping less retained earnings is a positive signal for increment in share price 
and this result also refutes dividend irrelevance theory.  
 
In practice, decisions as to whether to pay out dividends or not, how much of the profits to pay a 
dividend and in what form the dividend should be paid are influenced by many internal and external factors. 
According to (Alfred, D. D. 2007) there are many internal and external factors such as company's operational 
sector, nature of the company, liquidity constraints, tax constraints, reinvestment opportunity, risk factors, and so 
on can influence the dividend payout strategies of a company. 
 
Price-to-Earnings Ratio (P/E Ratio): The price-earnings ratio (P/E Ratio) is the ratio for assigning a 
value for a firm that measures its current share price relative to its per-share earnings (Nicholson, S. F.1960).The 
price-earnings ratio often called the P/E ratio or price to earnings ratio, is a market prospect ratio that calculates 
the market value of a stock relative to its earnings by comparing the market price per share by the earnings per 
share. 
The price-earnings ratio is normally calculated as the market value per share divided by earnings per 
share. In other words, the price-earnings ratio shows what the market is willing to pay for a stock based on its 
current earnings. 
 
Normally, a high P/E ratio implies that investors are anticipating higher earnings growth within the next 
years while firms with a lower P/E are expected lower growth (Ghaeli, 2017). Investors often use this ratio to 
evaluate what a stock’s fair market value should be by predicting future earnings per share. Companies with 
higher future earnings are usually expected to issue higher dividends or have appreciating stock in the future. 
There are two key drivers responsible for the increment in the P/E ratio; the first one is rapid growth in 
Price-Earnings ratios and the second one is slower growth in dividend yields. Rapid growth in price-earnings 
ratios simply shows the strong confidence of existing investors in a company due to the favourable market-wide 
environment. On the other hand, slower growth in dividend yields shows the company's management strategies 
focusing on reinvestment by employing a bigger chunk of retained earnings. Hence, sometimes lower dividend 
yields give hope to investors to accumulate even better return in future and this situation leads to a higher stock 
price as well as higher P/E ratio. These findings are consistent with Myers's (1984) pecking order and 
stakeholder hypotheses of dividend behaviour. There is also evidence that the P/E ratio is high when the price 
growth rate is high. This study indicates that a high P/E ratio signals faster growth in short-term stock prices 
(Raymond Y. C. Tse., 2002). 
Pankaj Kumar (2017), studied the influence of P/E ratio on the listed Indian automobile companies. The 
regression result showed a significant effect of P/E on the share price of automobile companies.  
Sanjeet Sharma (2011), conducted research on 115 listed companies of six different industries of India. 
Regression analysis showed that the P/E ratio exerts a significant positive impact on the share price of the 
companies. Similarly, Taimur Sharif et. al., (2015), studied the effect of PE ratio along with other firm-specific 
variable and they found that PE ratio is one of the main driving factors for the upward price movement of stocks. 
On the other hand, Onyango Benedict Enrile (2018) and Budhi Suparnihgsih (2017), respectively found positive 
yet insignificant effect and no significant effect of P/E ratio on the stock price. Similarly, AtyHerawati and 
Angger (2018) and George Gatheru Githinji (2011), observed no effect of the P/E ratio on the stock price. 
 
The Asset-Growth Effect: There is a significant and negative relationship between asset growth and 
future stock returns in emerging markets. Watanabe et al. (2012) find a weaker asset-growth effect in emerging 
markets relative to developed markets. In the context of this study, the asset growth effect has been analyzed and 
investigated, with a focus on the global financial crisis of 2008 and compare the existence of the asset-growth 
effect between normal and crisis periods. Since the financial crisis has effects globally on emerged as well as 
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emerging countries, our analysis on stocks traded in emerging markets provides the opportunity to identify 
whether mispricing or optimal investment explanation would find support in those countries. It has been 
observed that the asset-growth effect is stronger during the crisis period relative to more normal periods. During 
the peak year of the Global Financial Crisis, 2008, strong indicators have been found to support the existence of 
the asset growth effect during the crisis period, but not in other periods. 
That points to a significant association between the asset-growth effect and the global financial crisis 
period. The logic is that an episode of crisis gives investors the possibility to improve their assessment of the real 
value of firms’ investment even in those countries where the agency problems and asymmetric information are 
commonly assumed to be higher. 
In particular, the negative relation between asset growth and subsequent taxes returns holds only for the 
subset of firms with low innovation potential. Innovation based firms with high asset growth not only do not 
suffer negative excess returns subsequent to asset growth but actually, earn significantly positive subsequent 
excess returns. In addition, the significantly positive interaction effect between asset growth and innovative 
capacity on subsequent stock returns is robust to the industry effect, the size and BTM effects, and the IE effect 
documented in Hirshleifer et al. (2012). Asset Growth in innovative Pharmaceutical companies driven by huge 
investments and aggressive M&A strategy can generate new growth options. 
 
Gross Domestic Product (GDP): Gross Domestic Product (GDP) is the prime reflector of a country's 
economic growth; it gives a clear view about the degree of growth in almost every type of industry of a country. 
The high tide of economic growth marks the high probability of higher cash flow and low probability of the 
firm's chances to bankrupt, which provides a good environment for higher profitability, investment and so on 
which in turn increases value and stock prices of firms. On the other hand, during the time of economic 
downturn, the situation turns upside down.  
Economic growth occurs when an economy's productive capacity increases, which in turn is used to 
produce more goods and services. Economic growth is measured by an increase in the amount of goods and 
services that are produced in a country. Therefore, a growing economy produces more goods and services each 
successive time period. (Jhingan, M. 1997 Cited in Kampamba Shula (2017)).However, it is not always true that 
we get a correlation between GDP and stock return (www.wise-owl.com).   
 
Inflation Rate: Inflation is always and everywhere a monetary phenomenon in the sense that it is and 
can be produced only by a more rapid increase in the quantity of money than in output. Empirically, the 
variability of inflation tends to increase with the level of inflation, reinforcing the negative effect of higher 
inflation on the quantity of money demanded (Friedman., M. 1987). Higher inflation generally decreases the 
purchasing power of individuals and companies that eventually produces a negative influence on productivity, 
profitability and stock price of firms. Firms operate in a high inflation environment have a lower degree of 
willingness to opt debt financing which disrupts long investment plans and short-term purchasing power of firms 
(Öztekin., Ö. (2015).  
 
Interest Rate: Interest rates greatly affect a company's plan in fulfilling its capital needs, either by 
issuing equity securities or bonds. The low-interest rate will encourage investment and economic activity which 
generates a higher stock price as the result. (Thobarry, A. A. 2009 Cited in Kampamba Shula (2017). Similarly, 
Md. Gazi Salah Uddi and Md. Mahmudul Alam (2010) found an inverse relationship between the interest rate 
and share prices of listed companies at the Dhaka Stock Exchange. Low-interest rates will lead to lower 
borrowing costs since the borrower (the company) is charged to pay less interest. There is a negative relationship 
between the interest rate and borrowing capacity of the firm (Jõeveer, K. (2013). Firm, Country and 
Macroeconomic Determinants of Capital Structure: Evidence from Transition Economics. Journal of 
Comparative Economics, 41(1), 294-308). 
Corporate Tax: Reduction of government economic activity in the past 30 years in the wake of 
sweeping capitalism resulted in limiting both the scope and form of government taxation but the financial crisis 
of 2008 changed this paradigm, as it was expected from federal authorities to once again bail out the situation to 
restore calmness to markets. In this context, taxation became the most important tool of government policy 
(Renata Perić, LjubicaKordić, 2014). 
In the aftermath of the financial crisis of 2008, many pointed out that the reason lies in the fact that too 
many firms had loaded up on debt while relying on only a thin layer of equity. The reason is straightforward: 
whereas equity can absorb a business downturn – profits fall, but the firm does not immediately fail – debt is less 
forgiving because creditors do not wait around to be paid (Mark Roe, 2013, World Economic Forum).  The tax 
system that was skewed towards allowing, firms to use more debt than is safe. Tax deductions for interest 
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payments encourage them to borrow which in turn resulted in more tax-induced lending from financial 
institutions. The tax reform measures, brought in after the global crisis, had both positive and negative impacts 
on the global pharmaceutical investment outlook. Opportunities to access new markets mitigate risk due to 
pricing pressures and patent expirations continued to be the main impetus for the new operating model. 
 Corporate tax rates and repatriation as key drivers spurred M&A activity by making more cash 
available. 
 Many life sciences companies have chosen to keep their intellectual property (IP) rights offshore for tax 
reasons (Jeff Ellis and Dennis Howell, 2018). 
 R&D expenditures to boost new drug discovery and maintain a lucrative pipeline enjoyed cash 
infusions from various tax reforms. Counties like the US are also trying to retain intangible benefits by 
asking companies to amortize the cost of R&D performed onshore and offshore rather than deduct it all 
immediately. 
Exchange Rate: There is no theoretical consensus on the relationship between stock prices and exchange 
rates either. For instance, portfolio balance models of exchange rate determination postulate a negative 
relationship between stock prices and exchange rates and that the causation runs from stock prices to exchange 
rate. In contrast, a positive relationship between stock prices and exchange rates with the direction of causation 
running from exchange rates to stock prices can be explained as follows: domestic currency depreciation makes 
local firms more competitive, leading to an increase in their exports. This, in turn, raises their stock prices. 
A weak or no association between stock prices and exchange rates can also be postulated. The factors/news 
that causes changes in exchange rates may be different from the factors that cause changes in stock prices. Under 
such a scenario, there should be no link between the said variables Muhammad, N and Rasheed, A.,(2002). 
Some studies have found a significant positive relationship between stock prices and exchange rates for 
instance Smith (1992); Solnik (1987)* and Aggarwal (1981)*, while others have reported a significant negative 
relationship between the two e.g., Soenen and Hennigar (1998)*.  On the other hand, there are some studies that 
have found very weak or no association between stock prices and exchange rates, for instance, Franck and 
Young (1972); Bartov and Bodnor (1994)*. Note: *references are cited in Muhammad, N and Rasheed, 
A.,(2002) 
3. Methodology 
3.1. Data Collection: 
The data for this research work has been collected from the different relevant secondary sources such as 
the annual stock price of companies collected from www.Investing.com, other internal data of companies, for 
instance ROE, EPS, DPS, DPR, P/E ratio, and asset from Thomson Router EKion Data Stream, Macroeconomic 
data such as GDP, Inflation Rate, etc from www.knoema.com, and Currency Exchange Rate from 
www.poundsterlinglive.com. Since this research study is related to the pharmaceutical industry of emerging and 
emerged markets, quantitative data of twenty listed companies selected from emerging market (India) and twenty 
listed companies form emerged market (USA, Germany, France, United Kingdom, and Switzerland) have been 
sampled and analyzed.  
Two-panel data have been constructed, first one for the emerging market from the year 2008 to the year 
2017 with 200 observations and the second one for the emerged market for the same period with 181 
observations.  
In this study, selected companies were chosen based on their home countries and stock prices of those 
companies, belonging to their home stock exchanges, were collected along with other firm-specific data, 
retrieved from Thomson Ekion data stream. Since stock prices, EPS, DPS, and Asset of every company were 
collected in their local currency units, the currencies have been converted into US dollars, for the sake of 
congruency. 
The reason behind selecting twenty companies is because most of the mid-sized and small-sized 
companies of the emerged markets are privately held and not listed in stock exchanges. Similarly, due to many 
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negative and unavailable values of Earnings per share and dividend per share respectively, only 181 observations 
were made for the emerged market companies. 
3.2. Research Methodology 
The multiple regression method has been employed in this study in order to understand the relationship 
between several independent variables and the dependent variable. The independent variables used in this study 
are namely ROE, EPS, DPS, DPR, PER, ASSET, GDPGR, INFR, INTR, CT, and EXCHR whereas the 
dependent variable is MPS. Moreover, panel data model is being used in current course of investigation. There 
are several reasons behind using panel data, such as higher number of informative data, higher level of 
divergence among data, lower chance of collinearity among variables and more degree of freedom, which 
contribute towards constructing a more efficient data model. 
Four steps have been employed: 
 Descriptive statistical analysis to obtain the overview of data in terms of mean, maximum, 
minimum, sum, standard deviation, kurtosis, and so on 
 Correlation test has been employed to check the degree of Multicollinearity. 
 The following are the two types of panel analytic models have been considered: (1) Fixed effect 
model and (2) Random effect model. The fixed effect model is the divergence across cross-
sectional units which can be represented in divergence in the constant term and the intercept term 
of the regression model varies across the cross sectional units whereas the random effect model, the 
individual effects are randomly dispersed across the cross-sectional units and in order to represent 
the individual effects, the regression model is specified with an intercept term which represents an 
overall constant term (Seddighi, 2000) 
 In order to obtain better statistical model between Fixed Effect and Random Effect, the Hausman 
test has been used 
 Fixed effect Panel data regression model has been used to investigate simulations and partial effect 
of independent variables on dependent variables 
 
 
3.3. Research Hypothesis 
This section aims at providing a specific, clear, and testable proposition or predictive statement about 
the possible outcome of this study based on various variables and relationships between them in the context of 
the Pharmaceutical industry. Specifying the research hypotheses is one of the most important steps in planning a 
quantitative research study and it typically states a priori expectation about the research outcome in research 
hypotheses, because the design of the research often is determined by the stated hypotheses. 
 
Figure 2: Conceptual Framework Figure 
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Table1: Summary Table of Variables, Expected Hypothesis, and Studied Previous results 
 
3.4.    The Model 
MPS it = β0 + β1 ROE it + β2 EPS it + β3 DPS it + β4DPR it + β5 PER it + β6 LASSET it + β7 GDPGR it + β8 INFR 
it + β9 INTR it + β10 CT it + β11 EXCHR it + Ø it 
 MPS it = Market Prices of Share for the Pharmaceutical Companies during the period t 
 ROE it = Effect of Return on Equity (ROE) on MSP of the Pharmaceutical Companies during the 
period t 
 EPS it = Effect of Earnings per Share (EPS) on MSP of the Pharmaceutical Companies during the 
period t 
 DPS it = Effect of Dividend per Share (DPS) on MSP of the Pharmaceutical Companies during the 
period t 
 DPR it = Effect of Dividend Pay Ratio (DPR) on MSP of the Pharmaceutical Companies during the 
period t 
 PER it = Effect of Price Earnings Ratio (PER) on MSP of the Pharmaceutical Companies during the 
period t 
 ASSET it = Effect of Log of Total Assets (LASSET) on MSP of the Pharmaceutical Companies during 
the period t 
 GDPGR it= Effect of GDP (GDPGR) on MSP of the Pharmaceutical Companies during the period t 
 INFR it= Effect of Inflation Rate (INFR) on MSP of the Pharmaceutical Companies during the period t 
 INTR it= Effect of Interest Rate (INTR) on MSP of the Pharmaceutical Companies during the period t 
 CT it= Effect of Corporate Tax (CT) on MSP of the Pharmaceutical Companies during the period t 
 EXCHR it= Effect of Currency Exchange Rate (EXCHR) on MSP of the Pharmaceutical Companies 
during the period t 
 
β0 = Intercept 
β1 – β11 = Coefficient parameters 
Øit = error term 
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4. Findings and Analysis 
4.1. Descriptive Statistics Analysis 
 
MPS ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
 Mean  5.017152  0.214122  0.263590  0.047207  0.208234  20.55632  5.780051  0.070600  0.077300  0.068960  0.338670  53.86850
 Median  3.019759  0.186500  0.194419  0.034325  0.200525  18.02119  5.610477  0.069000  0.092500  0.073200  0.339900  52.62000
 Maximum  32.14881  0.816000  1.572172  0.301864  1.568615  275.6667  9.155685  0.103000  0.110000  0.080000  0.346100  66.25500
 Minimum  0.135349 -0.070000  0.009611  0.000000  0.000000  0.736363  3.319507  0.039000  0.036000  0.052500  0.324400  39.98000
 Std. Dev.  5.381683  0.118203  0.231940  0.040955  0.160171  22.95119  1.378394  0.016529  0.025755  0.009534  0.007619  8.773534
 Skewness  2.114633  1.416436  2.656942  2.318320  4.871247  7.495629  0.070622  0.061060 -0.407024 -0.467803 -1.027661 -0.031573
 Kurtosis  8.321841  6.664292  13.18731  11.73509  39.16005  79.64759  2.240334  3.005369  1.491282  1.722949  2.725734  1.646541
 Jarque-Bera  385.0724  178.7683  1100.156  815.0016  11687.21  50829.93  4.975352  0.124520  24.49088  20.88515  35.82978  15.29866
 Probability  0.000000  0.000000  0.000000  0.000000  0.000000  0.000000  0.083103  0.939639  0.000005  0.000029  0.000000  0.000476
 Sum  1003.430  42.82440  52.71798  9.441383  41.64673  4111.265  1156.010  14.12000  15.46000  13.79200  67.73400  10773.70
 Sum Sq. Dev.  5763.540  2.780413  10.70540  0.333786  5.105326  104824.6  378.0942  0.054368  0.132002  0.018088  0.011552  15318.00
 Observations  200  200  200  200  200  200  200  200  200  200  200  200  
Table2:  Results Descriptive Statistics Analysis of Indian Pharmaceutical companies (Processed by 
EViews-10) 
 
MPS ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
 Mean  182.5609  0.103425  2.401576  1.345293  0.868461  172.6613  8.820834  0.012310  0.095880  0.005643  0.307701  0.909303
 Median  42.15102  0.143000  1.922450  1.119050  0.431267  17.55490  9.940290  0.017000  0.015000  0.002500  0.341500  1.000000
 Maximum  3789.540  1.030000  17.26635  8.345960  80.00000  7233.280  12.26881  0.039000  1.650000  0.039500  0.350000  1.064100
 Minimum  1.620000 -4.647000 -5.710000  0.000000 -10.94737 -497.1429  3.081910 -0.056000 -0.011000 -0.007500  0.177700  0.605000
 Std. Dev.  559.6947  0.413980  3.588705  1.612761  6.013378  700.1737  2.530846  0.016686  0.357660  0.007692  0.063275  0.130422
 Skewness  4.698629 -7.659486  1.383203  2.474909  12.65399  6.505117 -0.520661 -1.686224  4.120806  1.835959 -1.242271 -0.964057
 Kurtosis  25.29681  88.33408  6.430707  10.17754  167.6029  57.32034  1.968180  5.564488  18.00747  7.947771  2.812989  2.350414
 Jarque-Bera  4878.801  62638.14  161.8562  576.4683  209165.2  25869.71  17.90837  149.5834  2442.903  316.3618  51.73272  34.49657
 Probability  0.000000  0.000000  0.000000  0.000000  0.000000  0.000000  0.000129  0.000000  0.000000  0.000000  0.000000  0.000000
 Sum  36512.18  20.68508  480.3152  244.8433  157.1914  34359.60  1764.167  2.462000  19.17600  1.128600  61.54020  181.8605
 Sum Sq. Dev.  62338370  34.10449  2562.882  470.7808  6508.929  97068151  1274.631  0.055403  25.45623  0.011775  0.796738  3.384965
 Observations  200  200  200  182  181  199  200  200  200  200  200  200  
Table3: Results Descriptive Statistics Analysis of US & European Pharmaceutical companies (Processed 
by EViews-10) 
 
For Indian pharmaceutical companies, Table 2 shows descriptive statistics analysis of 200 observations 
of for one dependent variable and twelve independent variables. In the case of US and European pharmaceutical 
companies, Table 3 shows descriptive statistics analysis of DPS and DPR with 181 observations, PER with 199 
observations and rest of variables with 200 observations.  
Descriptive statistical analysis of MPS for US and European pharmaceutical companies reflects a key 
difference from Indian pharmaceutical companies by having a huge gap between the minimum (1.620000) and 
maximum (3789.540) MSP value, much higher mean (182.5609), and standard deviation (559.6947). This result 
shows that few companies have had very high share price throughout the taken time period. Similarly, for US 
and European pharmaceutical companies, other variables such as ROE, EPS, DPR, and PER are swinging from 
higher negative value for the minimum to higher positive values for maximum. Moreover, other statistical 
parameters for instance mean and standard deviation are also showing value on the higher side. The reason 
behind this surge could be attributed to a much better performance of few companies over others. 
In the case of Indian pharmaceutical companies, MSP variable has a moderate range from minimum 
(0.135349) to maximum (32.14881) with mean of 5.017152 and standard deviation 5.381683. Similarly, other 
variables such as EPS, DPS, DPR, LASSET, and PER are also showing moderate variation in values for 
minimum, maximum, mean, and standard deviation.  Results show that throughout the observed time period, 
most of the Indian pharmaceutical companies in this study had performed in a reasonable manner. 
Descriptive statistical analysis of Indian as well as US and European pharmaceutical companies also 
depicts that dependent variable (MPS) and many independent variables have skewness greater than 1, which 
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shows high positive skewness whereas few variables have skewness less than -1, which shows high negative 
skewness. Both scenarios explain that data is not symmetrical. However, few variables have positive or negative 
skewness near to 0 which reflects that these variables have better symmetrical distribution than their peers.  
Since all variables have Kurtosis value more than 0, it infers that data distribution of variables has a 
heavier tail, called leptokurtic distribution. Furthermore, Kurtosis results also show that variables are not 
distributed symmetrically. In case of Indian pharmaceutical companies, Jarque-Bera test for checking the 
symmetrical distribution of variables reflects that except LASSET and GDPGR, other variables have probability 
value less than 5%, which shows that variables are not normally distributed. However, in case of US and 
European pharmaceutical companies, Jarque- Bera test for checking the symmetrical distribution of variables 
shows each variable having probability value less than 5%, indicating that variables are not normally distributed. 
 
4.2. Correlation Analysis 
ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
ROE  1.000000  0.480539  0.263484 -0.136942 -0.161969  0.221006 -0.055083  0.104760  0.052074 -0.074084 -0.156407
EPS  0.480539  1.000000  0.723002 -0.207805 -0.075762  0.128634 -0.024787 -0.269697  0.061018  0.091441  0.249788
DPS  0.263484  0.723002  1.000000  0.124588 -0.053951 -0.013739  0.034329 -0.222783  0.061242  0.098134  0.229039
DPR -0.136942 -0.207805  0.124588  1.000000  0.591633 -0.272037 -0.000456  0.097938  0.088633 -0.084579 -0.021667
PER -0.161969 -0.075762 -0.053951  0.591633  1.000000  0.093046  0.077463 -0.320882  0.059757  0.175649  0.312853
LASSET  0.221006  0.128634 -0.013739 -0.272037  0.093046  1.000000 -0.000143 -0.168783  0.038952  0.060398  0.167452
GDPGR -0.055083 -0.024787  0.034329 -0.000456  0.077463 -0.000143  1.000000 -0.044101 -0.584998  0.289197  0.185959
INFR  0.104760 -0.269697 -0.222783  0.097938 -0.320882 -0.168783 -0.044101  1.000000 -0.009365 -0.643132 -0.842999
INTR  0.052074  0.061018  0.061242  0.088633  0.059757  0.038952 -0.584998 -0.009365  1.000000 -0.457664 -0.049103
CT -0.074084  0.091441  0.098134 -0.084579  0.175649  0.060398  0.289197 -0.643132 -0.457664  1.000000  0.582928
EXCHR -0.156407  0.249788  0.229039 -0.021667  0.312853  0.167452  0.185959 -0.842999 -0.049103  0.582928  1.000000  
Table4: Results Correlation Analysis of Indian Pharmaceutical companies (Processed by EViews-10) 
 
ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
ROE  1.000000  0.420612  0.329006 -0.003524  0.036733  0.374162  0.100853 -0.019127 -0.147015 -0.226923 -0.025139
EPS  0.420612  1.000000  0.655097 -0.040519 -0.120871  0.447783  0.078046 -0.074960 -0.277622 -0.391630  0.200210
DPS  0.329006  0.655097  1.000000 -0.008333 -0.067289  0.556479  0.073373 -0.055722 -0.261344 -0.494865  0.180711
DPR -0.003524 -0.040519 -0.008333  1.000000  0.265700 -0.003076  0.055695 -0.009277  0.049829  0.017572 -0.072630
PER  0.036733 -0.120871 -0.067289  0.265700  1.000000 -0.031576  0.090410 -0.034270  0.026866 -0.292712 -0.427684
LASSET  0.374162  0.447783  0.556479 -0.003076 -0.031576  1.000000  0.145368  0.072950 -0.180310 -0.110412  0.332583
GDPGR  0.100853  0.078046  0.073373  0.055695  0.090410  0.145368  1.000000  0.175232 -0.271363 -0.080916  0.153838
INFR -0.019127 -0.074960 -0.055722 -0.009277 -0.034270  0.072950  0.175232  1.000000 -0.054430  0.158937  0.143092
INTR -0.147015 -0.277622 -0.261344  0.049829  0.026866 -0.180310 -0.271363 -0.054430  1.000000  0.263986 -0.327848
CT -0.226923 -0.391630 -0.494865  0.017572 -0.292712 -0.110412 -0.080916  0.158937  0.263986  1.000000  0.165459
EXCHR -0.025139  0.200210  0.180711 -0.072630 -0.427684  0.332583  0.153838  0.143092 -0.327848  0.165459  1.000000  
Table5: Results Correlation Analysis of US & European Pharmaceutical companies (Processed by 
EViews-10) 
 
Based on table 4 and 5, the value of correlation coefficient among independent variables of Indian as 
well as US and European pharmaceutical companies can be seen. In the correlation matrix, a correlation 
coefficient shows the extent to which one variable is correlated with others. A positive correlation means any 
increment in one variable causes an increment in other variable and a decrement in one variable causes a 
decrement in other variable similarly in case of negative correlation it is vice versa i.e. an increment in one 
variable causes a decrement in other variables. 
In table 4, the correlation matrix of Indian pharmaceutical companies depicts the higher correlation 
between few variables for instance EPS has highest positive correlation value (0.723002) with DPS followed by 
a positive correlation value (0.591633) between DPR and PER. However, the highest negative correlation value 
(-0.842999) observed between INFR and EXCHR. 
The Correlation matrix of US and European pharmaceutical companies in Table 5, EPS has the highest 
positive correlation with DPS with a correlation value of (0.655097).  The second highest correlation in this 
matrix is the positive correlation value (0.556479) between DPS with LASSET. 
Multicollinearity does not affect the properties of the OLS estimators. The estimator remains unbiased 
and efficient. But the fact is that when multicollinearity is present in the data then the OLS estimators are 
imprecisely estimated (Paul). Since seriousness of multicollinearilty in dataset can be measured through the 
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degree of correlation among variables, generally, highest degree of accepted correlation between two variables 
should be less than 0.80 (Edhi, A., 2017). By analyzing the correlation matrices of both markets, it can be 
inferred that of the degree of correlation among most variables is less than 0.80. However, negative correlation 
value (-0.842999) is observed between INFR and EXCHR for Indian pharmaceutical market in Table 4 whereas 
and positive correlation value (0.143092) is observed between INFR and EXCHR for European pharmaceutical 
market. Since this study is primarily focusing on comparative analysis between two markets while keeping type 
and number of variables intact in both sides, this higher correlation between INFR and EXCHR for Indian 
pharmaceutical market in Table 4 has been overlooked.   
 
4.3. Regression Analysis 
F-TEST 
The F test is carried out to verify whether the independent variables ROE, EPS, DPS, DPR, PER, 
LASSET, GDPGR, INFR, INTR, CT, and EXCHR combined, can significantly influence the dependent variable 
MSP of companies. 
Hypothesis: There is a simultaneous significant influence of independent variables on the dependent 
variable.  
Indian Pharmaceutical companies US and European Pharmaceutical companies 
Result of the F test (simultaneous coefficient test) 
shows that F-statistic of 32.32335 with significance 
below (0.000000<0.05). It can be concluded that 
together with ROE, EPS, DPS, DPR, PER, LASSET, 
GDPGR, INFR, INTR, CT, and EXCHR have a 
simultaneous significant effect on MSP of Indian 
Pharmaceutical Companies.  
Hypothesis Accepted 
Result of the F test (simultaneous coefficient test) 
shows that F-statistic of 99.05622 with significance 
below (0.000000<0.05). It can be concluded that 
together with ROE, EPS, DPS, DPR, PER, LASSET, 
GDPGR, INFR, INTR, CT, and EXCHR have a 
simultaneous significant effect on MSP of US and 
European Pharmaceutical Companies.  
Hypothesis Accepted 
Regression Result Summary 
Dependent Variable: MPS
Method: Panel Least Squares




Total panel (balanced) observations: 200
Variable Coefficient Std. Error t-Statistic Prob.  
C -16.60750 16.20192 -1.025032 0.3068
ROE -8.035798 3.537531 -2.271584 0.0244
EPS 7.059722 2.073999 3.403919 0.0008
DPS 61.00841 9.119055 6.690212 0.0000
DPR -7.331832 2.236580 -3.278144 0.0013
PER 0.061568 0.013690 4.497197 0.0000
LASSET 2.031314 0.975845 2.081595 0.0389
GDPGR -1.596778 12.73396 -0.125395 0.9004
INFR -27.03355 15.69895 -1.721998 0.0869
INTR -15.50890 25.39091 -0.610805 0.5421
CT 37.90745 36.99307 1.024718 0.3070
EXCHR -0.045328 0.038517 -1.176839 0.2409
Effects Specification
Cross-section fixed (dummy variables)
R-squared 0.851585     Mean dependent var 5.017152
Adjusted R-squared 0.825239     S.D. dependent var 5.381683
S.E. of regression 2.249779     Akaike info criterion 4.601123
Sum squared resid 855.3947     Schwarz criterion 5.112362
Log likelihood -429.1123     Hannan-Quinn criter. 4.808013
F-statistic 32.32335     Durbin-Watson stat 1.564283
Prob(F-statistic) 0.000000
 
Figure 4: Regression Result of Panel Data of Indian Pharmaceutical companies (Processed by EViews-10) 
Regression result of panel data of Indian pharmaceutical companies summarizes the regression test 
model in the following sections. 
The regression output summary of Indian pharmaceutical companies revealed an R-squared value of 
0.851585 which means that 85.1585% of the variation in the market share price of Indian pharmaceutical 
companies can be explicated by the independent variables included in the current study. Result of the F-test 
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(simultaneous coefficient test) also shows that F-statistic value of 32.32335 with significance below 
(0.000000<0.05) validates the inclusive simultaneous effect of all independent variables on the market price of a 
share of Indian pharmaceutical companies. 
ROE for Indian Pharmaceutical companies has the negative coefficient value of -8.035798 and 
probability (0.0244<0.05), which implies that the ROE has a significant negative effect on the MSP that is why 
H0 can be deemed rejected. This result supports previous studies of Fitri Sukmawati and Innes Garsela (2016). 
Independent variable EPS with positive coefficient value of 7.059722 and probability value of 
(0.0008<0.05) reflects that EPS has a significant positive effect on MSP of Indian pharmaceutical companies 
and thus H1can be deemed validated, which falls in line with the previous studies of Budhi Suparnihgsih (2017), 
Ursula Tamuntuan (2015).  
Similarly, the regression output of DPS for Indian pharmaceutical companies gives a positive 
coefficient value of 61.00841 with a probability value of (0.0000<0.05). Therefore, DPS can be considered to 
have a significant positive effect on the market share price which ratifies H2and supports previous studies of 
Onyango Benedict Enrile (2018), Sanjeet Sharma (2011), etc.  
However, Regression output of DPR has the negative coefficient value of -7.331832 and probability 
value of (0.0013<0.05) which depicts DPR with the significant negative effect on the stock price that means H3 
is accepted and supports previous studies of Hunjra et. al.(2014). Regression output indicates that the estimation 
result of PER for Indian pharmaceutical companies shows a positive coefficient value of 0.061568 with a 
probability value of (0.0000<0.05). It reflects that the PER has a significant positive effect on the market share 
price, which is in line with H4and supports previous studies of Pankaj Kumar (2017), Sanjeet Sharma (2011). 
Similarly, Regression output result of LASSET with positive coefficient value of 2.031314 and 
probability value lower than the specified significance level of 5% (0.0389<0.05), reflects that the LASSET has 
a significant positive effect on the stock price of Indian Pharmaceutical companies, hence it can be concluded 
that H5 is accepted.  
Regression result of macroeconomic variables such as GDPGR, INFR, INTR, CT, and EXCHR doesn’t 
show any significant effect on the market share price of Indian pharmaceutical companies. Hence, hypothesisH6, 
H7, H8, H9, and H10 are rejected.  
Dependent Variable: MPS
Method: Panel Least Squares




Total panel (unbalanced) observations: 181
Variable Coefficient Std. Error t-Statistic Prob.  
C 1759.451 454.4975 3.871201 0.0002
ROE 24.38475 36.24807 0.672718 0.5022
EPS 3.928813 6.061408 0.648168 0.5179
DPS 33.59069 31.44775 1.068143 0.2872
DPR -3.617106 2.025520 -1.785767 0.0762
PER 0.112454 0.026697 4.212300 0.0000
LASSET -21.14702 27.00078 -0.783201 0.4347
GDPGR -51.14591 688.0880 -0.074330 0.9408
INFR 14.50280 35.55964 0.407844 0.6840
INTR 2468.204 1683.991 1.465687 0.1448
CT -7053.961 1062.856 -6.636798 0.0000
EXCHR 743.9563 221.1875 3.363465 0.0010
Effects Specification
Cross-section fixed (dummy variables)
R-squared 0.951949     Mean dependent var 192.5727
Adjusted R-squared 0.942339     S.D. dependent var 586.6521
S.E. of regression 140.8712     Akaike info criterion 12.88825
Sum squared resid 2976705.     Schwarz criterion 13.43606
Log likelihood -1135.387     Hannan-Quinn criter. 13.11034
F-statistic 99.05622     Durbin-Watson stat 0.412744
Prob(F-statistic) 0.000000
 
Figure 5: Regression Result of Panel Data of US and European Pharmaceutical companies (Processed by 
EViews-10) 
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Regression result of panel data of US and European pharmaceutical companies summarizes the 
regression test model in the following sections. 
The regression output summary of US and European pharmaceutical companies revealed an R-squared 
value of 0.951949 which means that 95.1949 % of the variation in the market share price of US and European 
pharmaceutical companies can be explicated by the independent variables included in the current study. Result 
of the F-test (simultaneous coefficient test) also shows that F-statistic value of 99.05622 with significance below 
(0.000000<0.05) supporting the inclusive simultaneous effect of all independent variables on the market price of 
a share of US and European pharmaceutical companies. 
In the case of US and European pharmaceutical companies, most of the microeconomic variables such 
as ROE, EPS, DPS, DPR, and LASSAT don't have any significant effect on the market share price of US and 
European pharmaceutical companies. Hence, hypothesis H0, H1, H2, H3, and H5 are rejected. However, 
microeconomic variable namely PER shows a positive and significant effect on the market share price of US and 
European pharmaceutical companies with a coefficient value of 0.076573 and probability value (0.0000<0.05) 
respectively. Therefore, Hence, H4 is accepted and the result supports previous studies of Pankaj Kumar (2017), 
Sanjeet Sharma (2011). 
Regression result of macroeconomic variables such as GDPGR, INFR, and INTR don't show any 
significant effect on the market share price of US and European pharmaceutical companies. Hence, hypothesis 
H6, H7, and H8, are rejected. However, macroeconomic variables such as CT and EXCHR for US and European 
companies show the negative coefficient value of -7053.961 and positive coefficient 743.9563 respectively, 
while having probability value of (0.0000>0.05) for both variables. This result shows that CT and EXCHR have 
significant negative effect and positive effect respectively on the market share price of US and European 
pharmaceutical companies. Hence, hypothesis H9 is accepted which supports the previous study of Mark Roe 
(2013), whereas hypothesis H10 is rejected and supports the precious study of Solnik (1987) and Aggarwal 
(1981) and refutes the previous study done by Soenen and Hennigar (1998). 
 Indian Pharmaceutical companies US and European Pharmaceutical companies 
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Table 6: Comparative Analysis of Regression Result between Emerging and Emerged Market 
5. Conclusion and Recommendations 
The main objective of this study was to investigate the effect of internal (microeconomic) and external 
(macroeconomic) factors on the market price of a share of pharmaceuticals companies of emerging market 
(India) and emerged market (the US and Europe). During the course of study, 200 observations for emerging 
market and 181 observations for emerged markets, were examined and analyzed to understand the diverse 
behaviour of the same variables in emerging and emerged markets. The statistical estimation method was based 
on panel OLS regression while considering the fixed effect model. This research strived to establish an 
association between the market price of the share (MPS) and other eleven variables for both emerging and 
emerged markets separately. 
The empirical findings show a positive and significant relationship between EPS, DPS, PER, and 
LASSET with market price of the share (MPS) for emerging (India) market. This significant positive relation 
with MPS explains why higher EPS and DPS make companies more attractive for investment. Similarly, PER 
exerts the same impact on companies by making investors willing to buy their share at current market price even 
during the rally and thus fuel the overall upward growth. On the same note, higher LASSET growth boosts 
confidence in investors towards companies’ growth and investment outlook. Having said that, significant 
negative relation of ROE and DPR with MPS show that higher return on equity causes decrement in share price 
because of possible approach of middle size companies in aggressive reinvestment of retained earnings and 
investors’ money towards their expansion. Therefore, higher dividend payout ratio causes apprehension in 
investor’s mind about investment and growth policy of companies and that affects MPS in a negative manner.  
Since pharmaceutical companies are considered the non-cyclical industry, with better immunity against 
macroeconomic fluctuations, this study further reinforces that macroeconomic factors such as GDP growth, 
Inflation rate, interest rate and exchange rate do not affect significantly the market price of a share of 
pharmaceutical companies of the emerging market. In the case of emerged markets, most of the internal factors 
except PER do not show any significant effect on the MPS of US and European pharmaceutical companies. The 
possible reason behind this result could be the weak effect of ROE, EPS, DPS, and DPR on the MSP. As per 
data, these factors for many middle size pharmaceutical companies of the emerged market show that although 
they had negative EPS and they didn’t pay DPS due to negative net income, MPS wasn’t affected severely. 
Moreover, significant positive relationship between PER and MPS also brings to fore a crucial fact that despite 
successive bad results and unattractive dividend policies, investors showed their confidence in those companies. 
In emerged markets, the story is rather different. This study reveals macroeconomic factors such as GDP growth, 
Inflation rate and Interest rate, do not affect significantly the market price of a share of pharmaceutical 
companies of the emerged market. However, higher fluctuation in corporate tax and variation in exchange rates 
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show a significant negative and positive effect respectively on the MPS of pharmaceutical companies of the 
emerged market. The probable reason behind it could be the close relationship between the European and US 
economy. 
Possible recommendations promulgated by this study are stemmed firmly into the domains of micro and 
macroeconomics factors affecting key performance of pharmaceutical companies of emerging and emerged 
markets. During the research, pharmaceutical companies from five countries in the emerged market and one 
country in the emerging market have been considered to study the patterns of stock price changes. Along the 
same line, this methodology can also be implemented to study the pharmaceutical companies of each country 
separately, to achieve a more comprehensive and precise results, which can be helpful for investors and 
managers to understand and predict the stock patterns before investing their capital in pharmaceutical stocks. 
Also, the further studies can be helpful for the investors to comprehend the potentials of different countries in the 
field of pharmaceutical developments beforehand. In conclusion, it is worthwhile to mention that this study has 
paved the path to delve deeper into financial conditions of pharmaceutical companies of different countries from 
a novel perspective.    
 
6. Limitations 
Considering a few limitations of financial ratios, in some situations, financial ratios don't necessarily 
give very precise financial information such as distorted balance sheet of the firm due to inflation, different 
accounting policies in place and practices of different firms (https://www.thebalancesmb.com/limitations-of-
financial-ratio-analysis-393236). 
Since many middle and small-sized pharmaceutical companies in the USA and Europe are private 
entities and not listed in the stock exchange, only twenty companies have been taken from emerged markets in 
this study. 
Huge difference in operational, financial, other parameters between big and small emerged companies 
may cause biased regression results.  
This study gives a generalized idea about the effect of internal and external factors on the stock price of 
pharmaceutical companies in emerging and emerged market and how these factors behave differently in a 
different market. 
This study doesn't give a complete picture of share price fluctuation in the pharmaceutical sector of the 
entire emerging and emerged markets. 
In this study, in order to compare the regression results of pharmaceutical companies, in both emerging 
and emerged markets, fixed effect model has employed. Additionally, Hausman test has been performed and it 
was inferred that Random effect would have been more appropriate for Indian firms but considering the 
objective of this study, which is doing a comparative analysis of regression results of two different markets, the 
fixed effect was given chosen instead of random effect. 
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Firm Specific Data of Indian Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
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MPS: 5.349984582  
ROE: 14.50% 
EPS: 0.334566759 
DPS: 0.015418  
DPR: 0.046  
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Firm Specific Data of US and European Pharmaceutical Companies 
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Firm Specific Data of US and European Pharmaceutical Companies 
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2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 





2.5%  1.6%  2.2%  1.7%  2.6%  2.9%  1.5%  2.3%  




1.7%  1.5%  1.5%  2.1%  3.1%  2.3%  1.9%  1.8%  
Germany 0.8%  -
5.6%  
3.9%  3.7%  0.7%  0.6%  1.9%  1.5%  1.9%  2.5%  
France 0.2%  -
2.9%  
2.0%  2.1%  0.2%  0.6%  0.9%  1.1%  1.2%  1.8%  
Switzerland 2.1%  -
2.2%  
2.9%  1.8%  1.00%  1.9%  2.5%  1.2%  1.4%  1.1%  
 
      Key Macroeconomic Data of Selected Countries (GDP) 
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2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
India  9.1% 11.0% 9.5% 9.5% 10.0% 9.4% 5.8% 4.9% 4.5% 3.6% 
USA 3.8% -0.3% 1.6% 3.1% 2.1% 1.5% 1.6% 0.1% 1.3% 2.1% 
U K  3.6% 2.2% 3.3% 4.5% 2.8% 2.6% 1.5% 0.0% 0.7% 2.7% 
Germany 2.7% 0.2% 1.2% 2.5% 2.1% 1.6% 0.8% 0.1% 0.4% 1.7% 
France 3.2% 0.1% 1.7% 2.3% 2.2% 1.0% 0.6% 0.1% 0.3% 1.2% 
Switzerland 2.4% -0.5% 0.7% 0.2% -0.7% -0.2% 0.0% -1.1% -0.4% 0.5% 






















U K  3.95
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USA 35% 35% 35% 35% 35% 35% 35% 35% 35% 35% 
U K  30% 28% 28% 26% 24% 23% 21% 20% 20% 19% 





























Key Macroeconomic Data of Selected Countries (Corporate Tax) 
 
 
Country Year (April-March) 























39.94 45.90 47.35 45.53 47.90 54.38 60.45 61.13 65.17 67.03 
Key Macroeconomic Data of Selected Countries (Exchange Rate) 
https://www.poundsterlinglive.com 
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Year (January –December) 
Exchange rate against one $ USD  
2008 2009 2010 2011 2012 2013  2014 2015 2016 2017 
USA 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
United 
Kingdom 
0.695 0.619 0.638 0.646 0.618 0.605 0.641 0.675 0.813 0.74 
Germany 0.7194 0.697 0.7454 0.7729 0.7585 0.7263 0.7255 0.9181 0.947 0.8342 
France 0.7194 0.697 0.7454 0.7729 0.7585 0.7263 0.7255 0.9181 0.947 0.8342 
Switzerland 1.0641 1.0336 0.9321 0.9401 0.9158 0.8911 0.9892 0.9937 1.0178 0.9755 
Key Macroeconomic Data of Selected Countries (Exchange Rate) 
https://www.poundsterlinglive.com 
 
